Primary Health Properties PLC
("PHP" or the “Company”),
Director/PDMR Shareholding
Primary Health Properties PLC
Director Dealings - LTIP
Primary Health Properties PLC, announces that the Remuneration Committee has approved the following awards of nil-cost options under the Company’s 2021 Long-term Incentive Plan (“LTIP”) to Directors as follows:
|
Director |
Number of shares under option |
|
Mark Davies |
1,400,871 |
|
Richard Howell |
857,843 |
The number of nil-cost options were calculated by reference to a price of £0.9180, being the average of the closing middle market quotations for the Company’s ordinary shares on 22, 23 and 26 October 2026.
The nil-cost options will vest subject to the attainment of performance conditions measured over three years to 31 December 2028. The remuneration committee has the discretion to adjust the awards downwards at vesting for malus reasons. Details of the operation of the LTIP are set out in the Company’s 2025 Report and Accounts.
Details of the transactions referenced above are included below in accordance with the under Article 19 of the retained EU law version of the Market Abuse Regulation (Regulation 596/2014).
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
(a) |
Name |
Mark Davies |
|
|
2 |
Reason for notification |
||
|
(a) |
Position/Status |
Chief Executive Officer |
|
|
(b) |
Initial notification/amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
(a) |
Name |
Primary Health Properties PLC |
|
|
(b) |
LEI |
213800Y5CJHXOATK7X11 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date: and (iv) each place where transactions have been conducted |
||
|
(a) |
Description of the financial instrument, type of instrument and identification code |
Ordinary shares of 12.5p ISIN: GB00BYRJ5J14 |
|
|
(b) |
Nature of transaction |
Award of nil-cost options over the Company’s ordinary shares |
|
|
(c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil cost |
1,400,871 |
||
|
(d) |
Aggregated Information |
Single transaction: N/A |
|
|
(e) |
Date of transaction |
27 October 2026 |
|
|
(f) |
Place of transaction |
N/A |
|
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
(a) |
Name |
Richard Howell |
|
|
2 |
Reason for notification |
||
|
(a) |
Position/Status |
Chief Financial Officer |
|
|
(b) |
Initial notification/amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
(a) |
Name |
Primary Health Properties PLC |
|
|
(b) |
LEI |
213800Y5CJHXOATK7X11 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date: and (iv) each place where transactions have been conducted |
||
|
(a) |
Description of the financial instrument, type of instrument and identification code |
Ordinary shares of 12.5p ISIN: GB00BYRJ5J14 |
|
|
(b) |
Nature of transaction |
Award of nil-cost options over the Company’s ordinary shares |
|
|
(c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil cost |
857,843 |
||
|
(d) |
Aggregated Information |
Single transaction: N/A |
|
|
(e) |
Date of transaction |
27 October 2026 |
|
|
(f) |
Place of transaction |
N/A |
|
For further information
Mark Davies CEO Richard Howell CFO
Primary Health Properties PLC Primary Health Properties PLC
David Purcell Investor Relations
Primary Health Properties PLC
T: +44 (0) 7921 190 136
Sodali & Co Financial PR
Elly Williamson/Madeleine Gordon-Foxwell
T: +44 (0) 207 250 1446
Legal Entity Identifier: 213800Y5CJHXOATK7X11
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.